Avadel Pharmaceuticals (AVDL) EBT (2016 - 2021)
Historic EBT for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBT fell 34672.72% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 237958.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 36416.71% down from last year.
- As of Q4 2021, Avadel Pharmaceuticals' EBT stood at -$23.1 million, which was down 34672.72% from -$25.7 million recorded in Q3 2021.
- Over the past 5 years, Avadel Pharmaceuticals' EBT peaked at $36.3 million during Q2 2017, and registered a low of -$78.4 million during Q4 2018.
- Over the past 5 years, Avadel Pharmaceuticals' median EBT value was -$11.9 million (recorded in 2019), while the average stood at -$9.3 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' EBT soared by 264712.92% in 2017 and then plummeted by 127868.45% in 2018.
- Avadel Pharmaceuticals' EBT (Quarter) stood at -$5.7 million in 2017, then plummeted by 1278.68% to -$78.4 million in 2018, then skyrocketed by 30.43% to -$54.5 million in 2019, then skyrocketed by 90.5% to -$5.2 million in 2020, then crashed by 346.73% to -$23.1 million in 2021.
- Its last three reported values are -$23.1 million in Q4 2021, -$25.7 million for Q3 2021, and -$23.3 million during Q2 2021.